Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers

A method for detecting and treating mild cognitive impairment to slow the progression to Alzheimer's disease comprising

• measuring the level of each of three biomarkers (a), (b), and (c) in plasma, serum, or blood in a subject at the level of complement C3 and the level of Transthyretin of 37.4 μg/ml or less and 476.9 μg/ml or less, respectively, or the level of complement C3 and the level of Apolipoprotein A1 of 37.4 μg/ml or less and 1805 μg/ml or less, respectively by an anti-Complement C3 antibody, an anti-Apolipoprotein A1 antibody, and an anti-Transthyretin antibody;
• wherein,
• said biomarker (a) consists of an intact protein of Apolipoprotein A1 comprising the amino acid sequence represented by SEQ ID NO:
• 1 or a partial peptide thereof,
• said biomarker (b) consists of an intact protein of Transthyretin comprising the amino acid sequence represented by SEQ ID NO:2 or a partial peptide thereof, and
• said biomarker (c) consists of an intact protein of Complement C3 comprising the amino acid sequence represented by SEQ ID NO:3 or a partial peptide thereof;
• wherein the subject is determined as having mild cognitive impairment based on a combination of the level of complement C3 and the level of Transthyretin or a combination of the level of complement C3 and the level of Apolipoprotein A1 by a data processing device, wherein the data processing device is configured to calculate at least one regression equation to determine that the subject has mild cognitive impairment, and the data processing device comprises a memory part storing a program, wherein the program makes the controlling part conduct the determining step, the at least one regression equation comprises a combination of coefficients, and all the coefficients are obtained based on levels of the three biomarkers obtained by conducting the measuring step on a group of non-demented controls, a group of those having mild cognitive impairment, wherein the level of complement C3 and the level of Transthyretin of the subject are 37.4 μg/ml or less and 476.9 μg/ml or less, respectively, or the level of complement C3 and the level of Apolipoprotein A1 of the subject are 37.4 μg/ml or less and 1805 μg/ml or less, respectively;
• and
• administering to said subject a medication to suppress the progression of said impairment.